Change in goal attainment in those with lower or higher mean BG at baseline
Percent of subjects achievingtargets for gestational diabetes†
Percent of subjects achieving guideline target range goals at baseline and 10 weeks based on mean BG category at baseline*
BG < 6.1 mmol/L(% of subjectsat baseline)(n = 15,542)
BG <6.1 mmol/L(% of subjectsat 10 weeks)(n = 15,542)
Change from baselinein subjectsachieving this goal
BG ≥ 6.1 mmol/L(% of subjectsat baseline)(n = 10,840)
BG ≥ 6.1 mmol/L(% of subjectsat 10 weeks)(n = 10,840)
Change from baselinein subjectsachieving this goal
Achieved target for% readings < 3.0 mmol/L
96.8
97.6
+0.8 %pts
99.0
96.4
–2.6 %pts
Achieved target for% readings < 3.5 mmol/L
95.7
96.1
+0.4 %pts
99.2
95.4
–3.8 %pts
Achieved target for% readings 3.5 to 7.8 mmol/L
98.8
96.6
–2.3 %pts
58.5
79.5
+21.0 %pts
Achieved target for% readings > 7.8 mmol/L
68.6
68.0
–0.6 %pts
9.0
32.2
+23.2 %pts
*: Includes only subjects checking BG at least 3.5 times per day on average. All readings < 3.0, < 3.5, 3.5–7.8 and > 7.8 mmol/L identified and the percentage of subjects meeting each of the PwGDM target guidelines calculated at baseline and at 10 weeks. † Guidelines targets for readings in range are: < 1% readings < 3.0 mmol/L; < 4% readings < 3.5 mmol/L; > 80% readings 3.5 to 7.8 mmol/L; < 5% readings > 7.8 mmol/L. To convert mmol/L to mg/dL, multiply by 18.0182. %pts: percentage points; BG: blood glucose; PwGDM: people with gestational diabetes mellitus
MG, HC, and EH are all current employees of LifeScan.
Ethical approval
Users who downloaded the app were informed about personal data processing per the privacy policy and provided explicit consent for the use of de-identified data for analytics, research, and product development. No additional ethics committee approval was required, and no clinical sites or external investigators were involved.
Wang H, Li N, Chivese T, Werfalli M, Sun H, Yuen L, et al.; IDF Diabetes Atlas Committee Hyperglycaemia in Pregnancy Special Interest Group. IDF Diabetes Atlas: Estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group’s Criteria.Diabetes Res Clin Pract. 2022;183:109050. [DOI] [PubMed]
Sweeting A, Wong J, Murphy HR, Ross GP. A Clinical Update on Gestational Diabetes Mellitus.Endocr Rev. 2022;43:763–93. [DOI] [PubMed] [PMC]
HAPO Study Cooperative Research Group; Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes.N Engl J Med. 2008;358:1991–2002. [DOI] [PubMed]
American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024.Diabetes Care. 2024;47:S282–94. [DOI]
Yamamoto JM, Murphy HR. Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy.Diabetes Technol Ther. 2021;23:S8–14. [DOI] [PubMed] [PMC]
Murphy HR, Howgate C, O’Keefe J, Myers J, Morgan M, Coleman MA, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study.Lancet Diabetes Endocrinol. 2021;9:153–64. [DOI] [PubMed]
García-Moreno RM, Benítez-Valderrama P, Barquiel B, Pérez-de-Villar NG, Hillman N, Pablos DL, et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials.Diabet Med. 2022;39:e14703. [DOI] [PubMed]
Wyckoff JA, Brown FM. Time in Range in Pregnancy: Is There a Role?Diabetes Spectr. 2021;34:119–32. [DOI] [PubMed] [PMC]
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.Diabetes Care. 2019;42:1593–603. [DOI] [PubMed] [PMC]
Setford S, Smith A, McColl D, Grady M, Koria K, Cameron H. Evaluation of the performance of the OneTouch Select® Plus blood glucose test system against ISO 15197:2013.Expert Rev Med Devices. 2015;12:771–81. [DOI] [PubMed]
Bailey T, Chang A, Rosenblit PD, Jones L, Teft G, Setford S, et al. A comprehensive evaluation of the performance of the test strip technology for OneTouch Verio glucose meter systems.Diabetes Technol Ther. 2012;14:701–9. [DOI] [PubMed]
Poulter SE, Meloncelli N, Mack M. Use of a smartphone-based, interactive blood glucose management system in women with gestational diabetes mellitus: A pilot study.Diabetes Res Clin Pract. 2022;185:109224. [DOI] [PubMed]
Katz LB, Aparicio M, Cameron H, Ceppa F. Use of a Meter With Color-Range Indicators and a Mobile Diabetes Management App Improved Glycemic Control and Patient Satisfaction in an Underserved Hispanic Population: “Tu Salud”-A Randomized Controlled Partial Cross-Over Clinical Study.Diabetes Spectr. 2022;35:86–94. [DOI] [PubMed] [PMC]
Greenwood DA, Grady M. Healthcare Professional Perceptions of Blood Glucose Meter Features That Support Achievement of Self-Management Goals Recommended by Clinical Practice Guidelines.J Diabetes Sci Technol. 2021;15:1142–52. [DOI] [PubMed] [PMC]
Horgan R, Pierce-Williams R, Saccone G, Berghella V. Reminder systems to increase compliance with glucose logging in gestational diabetes: a systematic review and meta-analysis.Am J Obstet Gynecol MFM. 2022;4:100586. [DOI] [PubMed]
Pierce-Williams R, Sendek K, Firman B, Berghella V. Increased compliance with gestational diabetes mellitus glucose monitoring using a novel software.Am J Obstet Gynecol MFM. 2023;5:100890. [DOI] [PubMed]
Chehab RF, Ferrara A, Greenberg MB, Ngo AL, Feng J, Zhu Y. Glycemic Control Trajectories and Risk of Perinatal Complications Among Individuals With Gestational Diabetes.JAMA Netw Open. 2022;5:e2233955. [DOI] [PubMed] [PMC]
Wernimont SA, Sheng JS, Tymkowicz A, Fleener DK, Summers KM, Syrop CH, et al. Adherence to self-glucose monitoring recommendations and perinatal outcomes in pregnancies complicated by diabetes mellitus.Am J Obstet Gynecol MFM. 2019;1:100031. [DOI] [PubMed] [PMC]
Pigato F, Candido R, Zanette G, Zamagni G, Trojniak MP, Brunato B, et al. Gestational diabetes mellitus: Impact of adherence on patient management and maternal-neonatal complications.Prim Care Diabetes. 2023;17:486–92. [DOI] [PubMed]
Scifres CM, Mead-Harvey C, Nadeau H, Reid S, Pierce S, Feghali M, et al. Intensive glycemic control in gestational diabetes mellitus: a randomized controlled clinical feasibility trial.Am J Obstet Gynecol MFM. 2019;1:100050. [DOI] [PubMed]
Finneran MM, Kiefer MK, Ware CA, Buschur EO, Thung SF, Landon MB, et al. The use of longitudinal hemoglobin A1c values to predict adverse obstetric and neonatal outcomes in pregnancies complicated by pregestational diabetes.Am J Obstet Gynecol MFM. 2020;2:100069. [DOI] [PubMed]
Cosson E, Baz B, Gary F, Pharisien I, Nguyen MT, Sandre-Banon D, et al. Poor Reliability and Poor Adherence to Self-Monitoring of Blood Glucose Are Common in Women With Gestational Diabetes Mellitus and May Be Associated With Poor Pregnancy Outcomes.Diabetes Care. 2017;40:1181–6. [DOI] [PubMed]
Given JE, O’Kane MJ, Bunting BP, Coates VE. Comparing patient-generated blood glucose diary records with meter memory in diabetes: a systematic review.Diabet Med. 2013;30:901–13. [DOI] [PubMed]
Ryan EA, Savu A, Yeung RO, Moore LE, Bowker SL, Kaul P. Elevated fasting vs post-load glucose levels and pregnancy outcomes in gestational diabetes: a population-based study.Diabet Med. 2020;37:114–22. [DOI] [PubMed]